Literature DB >> 19571775

Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients.

Masatomo Miura1, Shigeru Satoh, Takenori Niioka, Hideaki Kagaya, Mitsuru Saito, Makoto Hayakari, Tomonori Habuchi, Toshio Suzuki.   

Abstract

The aim of this study was to examine whether a limited sampling strategy (LSS) to allow the simultaneous estimation of the area under the concentration-time curves (AUCs) of tacrolimus and mycophenolic acid (MPA) calculated in the early stage after renal transplantation could be applied to maintenance phase pharmacokinetics. Seventy Japanese patients were enrolled. One year after transplantation, samples were collected just before and 1, 2, 3, 4, 6, 9, and 12 hours after tacrolimus and mycophenolate mofetil administration at 9:00 am and at 9:00 pm. The prediction formulas on day 28 (tacrolimus AUC 0-12 = 7.04 x C 0h + 1.71 x C 2h + 3.23 x C 4h + 15.19 and 2.25 x C 2h + 1.92 x C 4h + 7.27 x C 9h + 6.61, and MPA AUC 0-12 = 0.26 x C 0h + 2.06 x C 2h + 3.82 x C 4h + 20.38 and 1.77 x C 2h + 2.34 x C 4h + 4.76 x C 9h + 15.94) were applied to pharmacokinetic data obtained at 1 year. Three error indices [percent mean prediction error (ME), % mean absolute error, and percent root mean squared prediction error (RMSE)] were used to evaluate the predictive bias, accuracy, and precision. The predicted AUC 0-12 of tacrolimus and MPA at 3 time points, C 2h-C 4h-C 9h, showed higher correlation with the measured AUC 0-12 of tacrolimus and MPA (r2 = 0.817 and 0.789, respectively) in comparison with those at C 0h-C 2h-C 4h. The values for the prediction formulas for tacrolimus AUC at 1 year using the C 2h-C 4h-C 9h combination yielded less than 5% for %ME and 15% for %RMSE. The %ME and %RMSE values of the prediction formulas for tacrolimus AUC using the C 0h-C 2h-C 4h combination were 6.3% and 15.9%, respectively. The %ME and %RMSE values of the prediction formulas for MPA AUC at 1 year using the C 0h-C 2h-C 4h combination were 5.9% and 25.8%, respectively, and those for the C 2h-C 4h-C 9h combination were 4.9% and 21.2%, respectively. AUC 6-12/AUC 0-12 of MPA 1 year after transplantation was significantly lower than 28 days after transplantation. An LSS using C 2h-C 4h-C 9h seems to be applicable for predicting the AUC of tacrolimus and MPA at either posttransplantation stage. The enterohepatic circulation of MPA was significantly reduced 1 year after transplantation. Therefore, 1 year after transplantation, the estimation of the AUC 0-12 of MPA for the C 0h-C 2h-C 4h equations was imprecise. It is important that the LSS includes C 9h because it contains information on the secondary plasma peak of MPA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571775     DOI: 10.1097/FTD.0b013e3181ae44b9

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus.

Authors:  Tomoyuki Enokiya; Kouhei Nishikawa; Yuichi Muraki; Takuya Iwamoto; Hideki Kanda; Yoshiki Sugimura; Masahiro Okuda
Journal:  J Pharm Health Care Sci       Date:  2017-06-24

2.  Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients.

Authors:  Jun Zhang; Zhi Sun; Zhenfeng Zhu; Jing Yang; Jian Kang; Guiwen Feng; Lin Zhou; Lihua Zuo; Yonggang Luo; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

3.  Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.

Authors:  Zheng Lu; Peter Bonate; James Keirns
Journal:  Br J Clin Pharmacol       Date:  2019-06-07       Impact factor: 4.335

Review 4.  Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases.

Authors:  Suguru Honda; Yasuhiro Katsumata; Kazunori Karasawa; Hisashi Yamanaka; Masayoshi Harigai
Journal:  JMA J       Date:  2019-09-10

5.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

6.  The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients.

Authors:  Liqin Zhu; Hao Wang; Xiaoye Sun; Wei Rao; Wei Qu; Yuan Zhang; Liying Sun
Journal:  J Pharm (Cairo)       Date:  2014-02-13

7.  A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity.

Authors:  Gerold Thölking; Katharina Schütte-Nütgen; Julia Schmitz; Alexandros Rovas; Maximilian Dahmen; Joachim Bautz; Ulrich Jehn; Hermann Pavenstädt; Barbara Heitplatz; Veerle Van Marck; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

8.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

9.  Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus.

Authors:  Michael Phan; Rishikesh Chavan; Richard Beuttler; Nicole Benipayo; Grace Magedman; David Buchbinder; Daniel Tomaszewski; Sun Yang
Journal:  Clin Transl Sci       Date:  2021-04-08       Impact factor: 4.689

10.  Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation.

Authors:  Stefan Reuter; Dirk Kuypers; Gerold Thölking; Brigitte Filensky; Ulrich Jehn; Katharina Schütte-Nütgen; Raphael Koch; Christine Kurschat; Hermann Pavenstädt; Barbara Suwelack
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.